Thromb Haemost 2000; 83(02): 209-211
DOI: 10.1055/s-0037-1613787
Rapid Communication
Schattauer GmbH

Outpatient Treatment of Pulmonary Embolism with Dalteparin

M. J. Kovacs
1   From the London Health Sciences Centre, University of Western Ontario, London, Ontario
,
D. Anderson
2   Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia
,
B. Morrow
1   From the London Health Sciences Centre, University of Western Ontario, London, Ontario
,
L. Gray
2   Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia
,
D. Touchie
3   Ottawa Civic Hospital, Ottawa, Ontario, Canada
,
P. S. Wells
3   Ottawa Civic Hospital, Ottawa, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 10 September 1999

Accepted after revision 08 October 1999

Publication Date:
11 December 2017 (online)

Summary

Background

Pulmonary embolism is a common complication of deep vein thrombosis. It has been established that low molecular weight heparin may be used to treat deep vein thrombosis or pulmonary embolism and randomized studies have established that outpatient management of deep vein thrombosis with low molecular weight heparin is at least as effective as in-hospital management with unfractionated heparin.

Methods

This was a prospective cohort study of eligible patients with pulmonary embolism managed as outpatients using dalteparin (200 U/kg s/c daily) for a minimum of five days and warfarin for 3 months. Outpatients included those managed exclusively out of hospital and those managed initially for 1-3 days as inpatients who then completed therapy o out of hospital. Reasons for admission included hemodynamic instability; hypoxia requiring oxygen therapy; admission for another medical reason; severe pain requiring parenteral analgesia or high risk of major bleeding. Patients were followed for three months for clinically apparent recurrent venous thromboembolism and bleeding.

Results

Between three teaching hospitals, a total of 158 patients with pulmonary embolism were identified. Fifty patients were managed as inpatients and 108 as outpatients. Of the outpatients, 27 were managed for an average of 2.5 days as inpatients and then completed dalteparin therapy as outpatients. The remaining 81 patients were managed exclusively as outpatients with dalteparin. For all outpatients the overall symptomatic recurrence rate of venous thromboembolism was 5.6% (6/108) with only 1.9% (2/108) major bleeds. There were a total of four deaths with none due to pulmonary embolism or major bleed.

Conclusions

This prospective study suggests that outpatient management of pulmonary embolism is feasible and safe for the majority of patients.

 
  • References

  • 1 Weinmann EE, Salzman EW. Deep-vein thrombosis. New Engl J Med 1994; 331: 1630-41.
  • 2 Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton J. Trends in the incidence of deep vein thrombosis and pulmonary embolus. Arch Intern Med 1998; 158: 585-93.
  • 3 Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
  • 4 Hull RD, Raskob GE, Rosenbloom D, Punju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. New Engl J Med 1990; 322: 1260-64.
  • 5 Ginsberg JS. Management of venous thromboembolism. New Engl J Med 1996; 335: 181628.
  • 6 Prandoni P, Lensing AWA, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, Cate JWT. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992; 339: 441-45.
  • 7 Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996; 100: 269-77.
  • 8 The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. New Engl J Med 1997; 337: 657-62.
  • 9 Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins: A meta-analysis. Arch Intern Med 1995; 155: 601-7.
  • 10 Hirsh J, Siragusa S, Cosmi B, Ginsberg JS. Low molecular weight heparins in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995; 74: 360-63.
  • 11 Lindmarker P, Holmstrom M, Granquist S. Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-90.
  • 12 Weitz JI. Low-Molecular-Weight Heparins. New Engl J Med 1997; 337: 688-98.
  • 13 Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, deHaes H, van den Belt AGM, Sagnard L, d’Azemar P, Büller HR. for the Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. New Engl J Med 1996; 334: 682-87.
  • 14 Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New Engl J Med 1996; 334: 677-81.
  • 15 Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism. New Engl J Med 1997; 337: 663-69.
  • 16 Kovacs MJ, Cruickshank M, Wells PS, Kim H, Chin-Yee I, Morrow B, Boyle E, Kovacs J. Randomized assessment of a warfarin nomogram for initial oral anticoagulation after venous thromboembolic disease. Haemostasis 1998; 28: 62-69.
  • 17 Cruickshank MK, Levine MN, Hirsh J, Roberts R. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151: 333-37.
  • 18 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon K, Julian JA, Math M. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. New Engl J Med 1999; 340: 901-7.
  • 19 Huisman MV, Buller HR, ten Cate JW. et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95: 498-502.
  • 20 Lindmarker P, Holmström M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. J Intern Med 1996; 240: 395-401.
  • 21 Wells PS, Kovacs MJ, Forgie MA, Bormanis J, Goudie D, Morrow B, Kovacs J. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin: A comparison of patient self-injection to home care injection. Arch Intern Med 1998; 158: 1809-12.